» Articles » PMID: 9242542

Fc GammaRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell Fc GammaRIIIa, Independently of the Fc GammaRIIIa-48L/R/H Phenotype

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1997 Aug 1
PMID 9242542
Citations 304
Authors
Affiliations
Soon will be listed here.
Abstract

We analyzed a genetic polymorphism of Fc gamma receptor IIIa (CD16) that is present on position 158 (Phe or Val) in the membrane-proximal, IgG-binding domain. With a polymerase chain reaction-based allele-specific restriction analysis assay we genotyped 87 donors and found gene frequencies of 0.57 and 0.43 for Fc gammaRIIIA-158F and -158V, respectively. A clear linkage was observed between the Fc gammaRIIIA-158F and -48L genotypes on the one hand and the Fc gammaRIIIA-158V and -48H or -48R genotypes on the other hand (chi2 test; P < .001). To determine the functional consequences of this Fc gammaRIIIa-158V/F polymorphism, we performed IgG binding experiments with natural killer (NK) cells from genotyped donors. All donors were also typed for the recently described triallelic Fc gammaRIIIa-48L/R/H polymorphism. NK cells were treated with lactic acid to remove cell-associated IgG. Fc gammaRIIIa(NK)-158F bound significantly less IgG1, IgG3, and IgG4 than did Fc gammaRIIIa(NK)-158V, irrespective of the Fc gammaRIIIa-48 phenotype. Moreover, freshly isolated NK cells from Fc gammaRIIIa-158VV individuals carried significantly more cytophilic IgG than did NK cells from Fc gammaRIIIa-158FF individuals. In addition, CD16 monoclonal antibody (MoAb) MEM154 bound more strongly to Fc gammaRIIIa-158V, compared with -158F, again independently of the Fc gammaRIIIa-48 phenotype. The binding of MoAb B73.1 was not influenced by the Fc gammaRIIIa-158V/F polymorphism, but proved to depend solely on the amino acid present at position 48 of Fc gammaRIIIa. In conclusion, the previously reported differences in IgG binding among the three Fc gammaRIIIa-48L/R/H isoforms are a consequence of the linked, biallelic Fc gammaRIIIa-158V/F polymorphism at amino-acid position 158.

Citing Articles

Locityper: targeted genotyping of complex polymorphic genes.

Prodanov T, Plender E, Seebohm G, Meuth S, Eichler E, Marschall T bioRxiv. 2025; .

PMID: 39990346 PMC: 11844405. DOI: 10.1101/2024.05.03.592358.


Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma.

Scalambra L, Ruzzi F, Pittino O, Semprini M, Cappello C, Angelicola S J Transl Med. 2025; 23(1):136.

PMID: 39885551 PMC: 11784117. DOI: 10.1186/s12967-025-06126-w.


Impact of Fc-gamma receptor IIIA polymorphism on late-onset neutropenia and clinical outcomes in kidney transplant recipients following rituximab induction therapy.

Tashiro Y, Hyodo Y, Kitamura S, Fujimoto T, Endo T, Nishioka S Clin Exp Nephrol. 2025; .

PMID: 39804516 DOI: 10.1007/s10157-024-02610-7.


Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients.

Schiele P, Kolling S, Rosnev S, Junkuhn C, Walter A, von Einem J Cells. 2025; 14(1.

PMID: 39791733 PMC: 11720420. DOI: 10.3390/cells14010032.


Novel and potent MICA/B antibody is therapeutically effective in mutant lung cancer models.

Kowash R, Sabnani M, Gray L, Deng Q, Saleh N, Girard L J Immunother Cancer. 2025; 13(1.

PMID: 39762078 PMC: 11749492. DOI: 10.1136/jitc-2024-009867.